Sermorelin

Also known as: GHRH(1-29), Growth Hormone-Releasing Hormone 1-29

Evidence Tier Bmedium riskintermediatenot approved

GHRH(1-29) analogue that stimulates pulsatile GH secretion, historically used in clinical settings.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

GH Axis

This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.

Overview

Sermorelin stimulates pituitary GH secretion via GHRH receptor signaling, intended to preserve pulsatile GH dynamics compared to exogenous GH. Pediatric therapy literature includes daily subcutaneous dosing around 30 Âµg/kg in GH-deficient children. GH-axis stimulation risks include glucose intolerance and theoretical neoplasia concerns when IGF-1 is elevated.

Research Details

Mechanism of Action

Stimulates pituitary GH secretion via GHRH receptor signaling; preserves pulsatile GH dynamics.

Study Dose Range

Pediatric: daily subcutaneous ~30 Âµg/kg in GH-deficient children.

Administration Routes

subcutaneous

Onset / Timeline

GH secretion changes occur acutely; body composition endpoints are months-horizon.

Expected Effects

GH axis stimulation; growth/body composition changes over months.

Adverse Effects

Glucose intolerance risk; theoretical neoplasia concerns with sustained IGF-1 elevation.

Contraindications

Active malignancy (by analogy to tesamorelin class warnings).

Interaction Notes

Unknown interaction profile outside supervised settings.

Related Goals

GH Axis Optimization

Known Interactions

caution with Ipamorelin

GHRH analog + GHS-R agonist: additive GH release plausible.

caution with GHRP-6

GHRH analog + GHS-R agonist: additive GH release plausible.

caution with GHRP-2

GHRH analog + GHS-R agonist: additive GH release plausible.

caution with MK-677

MK-677 and sermorelin both push GH-axis signaling through different levers; treat as additive endocrine load.

Available From

No vendors currently listed for this peptide.

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.